Table 3.
Cox regression model in unadjusted patients (i.e. all patients sample).
| PFS | OS | ||||
|---|---|---|---|---|---|
| Factor | Category | HR (95% CI) | p value | HR (95% CI) | p value |
| Smoking | No | 1 | 1 | ||
| Exsmoker | 0.73 (0.48 - 1.12) | 0.154 | 0.79 (0.45 - 1.35) | 0.373 | |
| Yes | 0.88 (0.59 - 1.32) | 0.537 | 1.08 (0.65 - 1.80) | 0.754 | |
| Sex | Male | 1 | 1 | ||
| Female | 1.06 (0.83 - 1.36) | 0.640 | 0.81 (0.60 - 1.11) | 0.190 | |
| ECOG PS | 0 | 1 | 1 | ||
| 1 | 1.95 (1.26 - 3.02) | 0.003 | 2.68 (1.34 - 5.14) | 0.003 | |
| 2 | 3.41 (1.75 - 6.64) | <0.001 | 5.27 (2.22 - 12.54) | <0.001 | |
| Age | <70 | 1 | 1 | ||
| ≥70 | 0.93 (0.73 - 1.18) | 0.535 | 0.96 (0.72 - 1.29) | 0.802 | |
| Histology | Adenocarcinoma | 1 | 1 | ||
| Sqamous | 1.03 (0.79 - 1.35) | 0.838 | 0.97 (0.70 - 1.34) | 0.852 | |
| Other | 1.00 (0.59 - 1.70) | 0.992 | 1.24 (0.69 - 2.25) | 0.473 | |
| Stage | 3 | 1 | 1 | ||
| 4 | 1.18 (0.61 - 2.32) | 0.622 | 1.18 (0.48 -2.90) | 0.712 | |
| PD-L1 Expression | <80 % | 1 | 1 | ||
| ≥80 % | 0.89 (0.70 - 1.14) | 0.354 | 0.98 (0.73 - 1.32) | 0.914 | |
| Therapy | P | 1 | 1 | ||
| P+CHT | 1.06 (0.76 - 1.46) | 0.746 | 1.07 (0.71 - 1.62) | 0.741 | |
ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; OS = overall survival; P = pembrolizumab; P + CHT = pembrolizumab + chemotherapy; PFS = progression free survival